CareDx (CDNA) Q4 2025 Earnings Call Transcript
The Motley Fool
by newsfeedback@fool.com (Motley Fool Transcribing)February 24, 2026
AI-Generated Deep Dive Summary
CareDx (CDNA) reported strong financial performance in its Q4 2025 earnings call, with total revenue reaching $108.4 million, up 25% year-over-year. The company’s Testing Services segment led the growth, generating $78.4 million in revenue, driven by increased adoption of AlloSure Kidney surveillance protocols and for-cause testing. Testing volume rose to approximately 53,000 tests, reflecting a 17% increase. Patient and Digital Solutions contributed $16.8 million, a 47% year-over-year jump fueled by MedActionPlan and ZynQAPI platforms, as well as its transplant-focused pharmacy business. Lab Product Revenue also grew to $13.3 million, a 17% increase due to HLA typing solutions and international expansion.
Non-GAAP gross margin remained steady at 68.5% for the quarter and 69.3% for the year. Adjusted EBITDA was $6.5 million, down 34% from the prior year, primarily due to a one-time $6.7 million cash bonus for nonexecutives. Despite this, Cash and Equivalents stood at $201.4 million at year-end with no debt. The company repurchased $88 million in shares during 2025, reducing outstanding shares by 9%. Cash Collections improved significantly to $115.8 million for the quarter, a 37% increase year-over-year, while DSO improved from 71 days to 41 days, a 42% reduction.
Verticals
financeinvesting
Originally published on The Motley Fool on 2/24/2026